Microbiotica

Meet our CEO Tim Sharpington at Microbiome Connect in Boston from 20th-21st November to discuss our innovative live biotherapeutic products in immuno-oncology and inflammatory bowel disease. Microbiotica’s platform enables high-resolution identification and analysis of microbiota at the species level, leading to more precise therapeutic targeting and the potential for significantly improved clinical outcomes. Our MELODY-1 trial in advanced melanoma has dosed its first patient with MB097, an oral live biotherapeutic product (LBP) designed to improve the efficacy of immune checkpoint inhibitors. COMPOSER-1 is our Phase 1b clinical trial of MB310, a monotherapy for treating ulcerative colitis, which is also actively recruiting patients. We’re looking forward to meeting others who are working to advance microbiome-based therapies. #Biotech #Pharma #ImmunoOncology #CancerResearch #Microbiome #IBS 🔗 https://lnkd.in/gNZWJzX3

🎙️ New Podcast Alert! Tim Sharpington and Trevor Lawley join Eliot Forster in the latest episode of new series The Life Sci Fantastic to discuss the potential of the human microbiome as a new treatment modality. Hear about: 🦠 The dynamic nature of our microbiome - antibiotics, diet and even where we live can shape our microbiome and, in turn, our health. 🌱 a future where monitoring and optimising our microbiome from birth could be routine, with specific bacteria used to prevent or treat diseases like cancer, IBD, and even mood disorders. 🔬 Our groundbreaking research suggests restoring the right gut bacteria could significantly improve outcomes. Tune in to hear more about our cutting-edge science and the exciting journey ahead for microbiome therapeutics 🎧 Listen now on Spotify: https://lnkd.in/en7j6_Qt  🎧 Available on Apple Podcasts: https://lnkd.in/ebksQmnm #Microbiome #CancerResearch #DrugDiscovery #Biotech #Immunotherapy #HealthcareInnovation

Matthew Robinson will be representing Microbiotica at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston on November 6th. Meet Mat to learn more about our Phase 1b trial (Melody-1) testing MB097 in advanced melanoma. MB097 is a defined consortium of nine bacterial strains designed to improve patient responses to immunotherapy. #biotech #pharma #ImmunoOncology #CancerResearch #SITC2024 #Microbiome 🔗 https://lnkd.in/ggphnMEm

⬇️Thank you Mike Scialom at Cambridge Independent for highlighting our exciting news of the first patient dosed in our MELODY-1 trial for advanced melanoma, to improve outcomes for patients who haven't responded to immunotherapies. We’ll be treating patients across our clinical trial centres in the UK, France, Italy, and Spain and anticipate initial data readouts by the end of 2025. 🔗https://lnkd.in/ezbTCwiv #Biotech #Microbiome #Pharma #Melanoma

Schedule a meeting with Tim Sharpington at BIO-Europe 2024 in Stockholm to discuss the future of precision microbiome therapies in immuno-oncology and inflammatory bowel disease.🤝 https://lnkd.in/dRGyPtmn We’re actively seeking partnerships with investors and collaborators to drive the next stage of our clinical and commercial growth. Learn about the latest progress in our pipeline: MELODY-1: Our international Phase 1b trial of MB097 in advanced melanoma, combining with MSD’s KEYTRUDA® (pembrolizumab). We’ve just dosed the first patient in this cutting-edge trial targeting patients who haven't responded to existing immunotherapies. COMPOSER-1: Our Phase 1b trial of MB310 in ulcerative colitis, aiming to revolutionizse outcomes bring new, safe and potentially disease modifying treatment options for patients with inflammatory bowel disease through microbiome-based therapies. Let’s connect and explore how we can collaborate to bring these innovative treatments to patients. 🤝 Schedule a meeting with Tim: https://lnkd.in/dRGyPtmn 🔗 #BIOEurope2024: https://lnkd.in/dnuNZ2D #Biotech #Pharma #Innovation #Microbiome #Oncology #CancerResearch #IBS Informa Connect Life Sciences

Immunotherapy has been life-saving for many patients, but there is still much work to be done for the many who don’t respond to treatment, or experience serious side effects.   We are therefore delighted to be a part of the industry consortium for the £21.9M MANIFEST programme, which aims, over four years, to identify predictive biomarkers in over 6,000 cancer patients. This continues our commitment to understanding how the microbiome can play a role in the development of biomarkers and therapeutics in cancer. https://lnkd.in/er8xmr5v 🔗 Discover our MELODY-1 trial: https://lnkd.in/e8Q5PzSE 🔬www.microbiotica.com #Microbiome #CancerResearch #Melanoma #Biotech #Pharma #Innovation #ClinicalTrials

We’re excited to be part of the newly launched MANIFEST consortium a £21.9M UK-wide initiative to advance cancer immunotherapy through trials involving 6,000 patients, pre-treatment and during treatment. By monitoring biomarkers in these cancer patients we're striving to better understand responses to immunotherapy treatment.   #Microbiome #CancerResearch #Immunotherapy #Biotech #Innovation

A major milestone as we can confirm that the first patient has been dosed in our international Phase 1b MELODY-1 trial of MB097, our precision microbiome co-therapy in advanced melanoma. Given as a co-therapy with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), MB097 aims to enhance immune response for patients who haven't responded to existing immunotherapies - representing up to 50% of advanced melanoma cases. MELODY-1 is set to recruit up to 40 patients across the UK, France, Italy, and Spain, with initial data readouts expected by the end of 2025. MB097, an orally administered live biotherapeutic product, contains a defined consortium of commensal bacterial strains designed to enhance the efficacy of immune checkpoint inhibitors. With the potential to transform treatment for patients who are resistant to current therapies, we’re looking forward to seeing how MB097 can impact cancer care. 🔗 Read the press release: https://lnkd.in/e8Q5PzSE 🔬www.microbiotica.com #Biotech #Pharma #Innovation #Microbiome #ClincialTrials #CancerResearch #DrugDevelopment #Melanoma

As a member of the European Microbiome Innovation for Health we congratulate them on their latest collaboration with the Microbiome Therapeutics Innovation Group (MTIG) to advance #microbiome drug development and strengthen international regulatory synergies! 👏

On World Cancer Research Day, we recognise the crucial role of innovative science in the fight against cancer, and are pioneering a new approach to cancer care by harnessing the power of the gut microbiome. Our immuno-oncology programme MB097 is a consortium of nine bacterial strains, which together comprise a specific microbiome signature that enables improved patient responses to immunotherapies, offering new hope for personalised cancer care in advanced melanoma. Together, we’re advancing towards a future where microbiome-driven treatments could transform the standard of cancer care. #Pharma #Biotech #WorldCancerResearchDay #CancerResearch #Microbiome #WCRD 🔗https://lnkd.in/eZmHmiF